Histone deacetylase inhibitors have generated keen interest as potential chemopreventive and chemotherapeutic agents due to their ability to induce cell cycle arrest, differentiation, and apoptosis in a diverse group of cancer derived cell lines. Activation of the 60 kDa nonreceptor tyrosine kinase, c-Src, has been a consistent finding in many tumors and tumor derived cell lines, and has been implicated in these same cellular processes. We have shown that the histone deacetylase inhibitors, sodium butyrate and Trichostatin A, repressed c-Src mRNA and protein expression in a dose-dependent manner in cell lines derived from cancers of the colon, breast and liver. Our group has previously identified two distinct promoters that are responsible for SRC transcription, separated by a distance of approximately 1 kb. Sodium butyrate and Trichostatin A strongly inhibited activity of each of these highly disparate SRC promoters, demonstrating histone deacetylase inhibitors directly repress SRC transcription. This repression did not require protein neosynthesis and was not associated with a decrease in binding of protein factors essential for either promoter's activity. Our finding that sodium butyrate and Trichostatin A inhibit both SRC promoters suggest this oncogene may be a major target of these agents, and may explain in part their anti-cancer activity.
Introduction
Sodium butyrate (NaB) is a naturally occurring short chain fatty acid generated in the colon by the anaerobic bacterial fermentation of dietary fiber (Topping and Clifton, 2001) . While NaB appears to play an essential role in the maintenance of a healthy mucosa (Hass et al., 1997; Luciano et al., 1996) it has generated most interest of late because of its ability to induce cell cycle arrest, differentiation and/or apoptosis in a variety of tumor derived cell lines (Gamet et al., 1992; Hague et al., 1993; Mandal and Kumar, 1996; Schwartz et al., 1998) . This discovery has provided an attractive rationale to explain the reported chemopreventive action of high fiber diets toward intestinal tumors (Reddy, 1995; Trock et al., 1990) , a hypothesis now backed by a number of animal and epidemiological studies (D'Argenio et al., 1996; McIntyre et al., 1993) . While the mechanisms by which NaB exerts its actions are not completely understood it is known to be a noncompetitive, reversible inhibitor of histone deacetylases (HDACs) (Marks et al., 2001b; Sealy and Chalkley, 1978) . This inhibition is believed to lead to a shift in the cell towards overal histone acetylation by various histone acetyltransferases (HATs). The resulting effect on chromatin is associated with dramatic, but highly specific, changes in gene expression profiles (Iacomino et al., 2001; Marks et al., 2001b) . This includes the induction of p21 WAF1 (Archer et al., 1998) , the potent mediator of cell cycle arrest, and the inhibition of other genes associated with cellular proliferation and differentiation such as c-myc (Souleimani and Asselin, 1993) . Similar effects to those observed with NaB can also be seen with more potent and specific HDAC inhibitors, such as Trichostatin A (TSA) and related compounds (Richon et al., 2000; Suzuki et al., 2000; Vigushin et al., 2001; Yoshida et al., 1990) . Clinical trials are currently underway to examine the effectiveness of these agents as potential anti-neoplastics (Marks et al., 2001b) .
Our laboratory has been studying various aspects of the human SRC gene, which encodes the non-receptor tyrosine kinase, pp60 c-src Ritchie et al., 2000) . Activation and/or overexpression of c-Src in colon cancer has been a frequent observation made over the years by numerous groups (Irby and Yeatman, 2000) . Most recently, activating and transforming mutations in the SRC gene were identified in a small percentage of advanced colon tumors (Irby et al., 1999) . In addition, c-Src activation, often associated with the overexpression of Epidermal Growth Factor Receptor (EGFR) family members, has been shown to be a critical factor in the development of other important cancers, especially those of the breast (Biscardi et al., 1998 (Biscardi et al., , 1999 Verbeek et al., 1996) . While the precise role c-Src plays in the development of these cancers is not clear, various studies have strongly implicated c-Src in cellular proliferation, tumorigenicity, survival and angiogenesis (Biscardi et al., 1999; Irby and Yeatman, 2000) . Previously, we described ubiquitous and tissue specific SRC promoters which we termed SRC1A and SRC1a respectively (Bonham and Fujita, 1993; Bonham et al., 2000; Ritchie et al., 2000) . These two promoters are separated by approximately 1.0 kb and each is associated with its own distinct noncoding exon. The two resulting mRNA species differ in the first 150 -200 nucleotides of the 5' noncoding region but encode identical c-Src proteins. The distal SRC1a promoter is regulated by Hepatic Nuclear Factor (HNF)-1a and activity is restricted to tissues which express this transcription factor, such as liver, kidney, pancreas and gut. In contrast, the proximal SRC1A promoter is regulated by members of the Sp1 family and is expressed, to some extent, in almost all tissues examined. Recently, we reported that transcriptional upregulation of SRC in a subset of colon cancer cell lines was responsible for the observed c-Src overexpression and activation (Dehm et al., 2001) .
A number of groups have examined the effect of NaB on the differentiation of colon cancer cell lines (Gamet et al., 1992; Iacomino et al., 2001; Mariadason et al., 2000; Singh et al., 1997) and an early report from Bolen's group also noted reduced levels of c-Src protein associated with NaB mediated differentiation (Foss et al., 1989) . Given that c-Src is now considered an important contributing factor to the development of various cancers, we hypothesized that NaB and other more specific HDAC inhibitors such as TSA, might influence c-Src gene expression. In this study we report that NaB and TSA were able to rapidly and effectively inhibit transcription from both SRC promoters, resulting in a dramatic reduction in c-Src mRNA and protein in a variety of human cancer cell lines. In our comparison of the dose dependence and kinetics of maximal c-Src repression or p21 WAF1 induction, we noted a very strong correlation. In addition, we found c-Src expression did not require protein neosynthesis. These findings suggest SRC is a major, common target of HDAC inhibitors and, in addition to p21 WAF1 , may play an important role in the induction of cell cycle arrest, differentiation and apoptosis by such agents.
Results
NaB and TSA inhibit c-Src mRNA and protein expression Previously we described the overall expression level and relative promoter usage for the SRC gene in a number of human tumor cell lines Dehm et al., 2001; Rajala et al., 2000) . For the current study we chose to concentrate on four cell lines, representative of the diversity of c-Src expression we encountered. HT29 and SW480 are colon cancer cell lines that express high and low levels of c-Src respectively. HT29 utilizes both promoters equally, while SW480 predominantly uses the SRC1A promoter. T-47D is a breast cancer cell line, which expresses relatively high levels of c-Src, exclusively from the SRC1A promoter. In contrast, HepG2 is a hepatocellular carcinoma cell line that expresses levels of c-Src comparable to HT29 cells and predominantly utilizes the SRC1a promoter Rajala et al., 2000 , and data not shown). Despite this heterogeneity in expression levels and promoter utilization, a 24 h exposure to NaB resulted in a dose dependent repression in c-Src mRNA levels in all cells, with the optimal dose in the 2 -10 mM range (Figure 1a , upper panels). This dose was also found to be optimal for the well-characterized induction of p21 WAF1 (Figure 1a , lower panels) and is similar to that normally found in the human colon (Topping and Clifton, 2001) . Similar results were also seen for T-47D and HepG2 cells (not shown). Time course studies revealed NaB treatment (5 mM) dramatically inhibited c-Src mRNA expression over the 24 h period, with obvious reductions within as little as 6 h ( Figure 1b, upper panels) . In contrast, when these Northerns were reprobed with p21 WAF1 we observed a dramatic induction of p21 WAF1 mRNA in all cases ( Figure 1b , lower panels). Interestingly, the time points for maximal induction of p21 WAF1 appeared to correlate very well with the maximal repression of cSrc mRNA. To determine if the repression of c-Src mRNA levels could be attributed to NaB's known property as an inhibitor of HDACs we repeated these experiments with TSA. We found that TSA treatment of these cell lines resulted in a similar decrease in c-Src mRNA expression; an example of this is shown in Figure 1c for HT29 cells. However, the effect we observed with TSA appeared transient in most cell lines studied, and c-Src mRNA expression was elevated back to untreated levels after 24 h of exposure to TSA. We also noted a co-ordinate decrease in p21 expression levels during this 24 h TSA treatment time point. Lastly, we carried out Western blot analysis to demonstrate that the down-regulation in c-Src mRNA was also reflected at the protein level. An example of these analyses is shown in Figure 1d for treatment of HT29 cells with NaB (5 mM) and TSA (1 mM), or treatment of SW480 cells with TSA.
Butyrate mediated repression of c-Src expression occurs in the absence of new protein synthesis
To determine if the inhibition of c-Src expression was a direct effect on c-Src gene expression we repeated the experiments in the presence of the protein synthesis inhibitor cyclohexamide (50 mM). As shown in Figure  2 , cyclohexamide treatment alone resulted in a significant induction of c-Src mRNA in HT29 cells. However, despite this induction cyclohexamide was unable to block the dramatic repression of c-Src by NaB. When these blots were reprobed for p21 WAF1 expression we noted a similar induction of p21 WAF1 with cycloheximide alone. In contrast to c-Src mRNA though, p21 WAF1 mRNA levels were dramatically amplified in the presence of NaB. Again, similar results were seen in the other three cell lines (results not shown). To date we have made similar observations in a total of 11 human cell lines of varying origin (results not shown). Taken together these data suggest the SRC gene is a common and direct target for downregulation by NaB and TSA, irrespective of either the relative promoter usage or overall level of c-Src mRNA expression. The ability of the more specific HDAC inhibitor TSA to mirror the NaB results also suggests that the mechanism involves changes in the balance of HAT/HDAC activity and not some other NaB related response. The inability of cyclohexamide to block the NaB mediated repression of c-Src mRNA demonstrates that new protein synthesis is not a requirement.
NaB and TSA inhibit activity of both the SRC1A and SRC1a promoters
Since both NaB and TSA inhibited c-Src mRNA expression we next asked if these agents were capable of modulating c-Src transcriptional activity. This question was complicated by our recent observation that two independent and highly dissimilar promoters regulate expression of the SRC gene . Activity of the SRC1a promoter is absolutely dependent on the presence of an intact HNF-1 binding site at position 756 to 735 . In contrast, the SRC1A promoter is regulated predominantly by two Sp1 binding sites termed GC1 and GA2 . We therefore carried out transient transfection assays in HepG2 (Figure 3a ) and SW480 (Figure 3b ) cells, which express high and low levels of c-Src, respectively, using a series of plasmids containing the CAT reporter gene under the control of either the ubiquitous SRC1A (0.38SRC1A-CAT) or the tissue specific SRC1a (7145SRC1a-CAT) promoter. Cells were transiently transfected and after 24 h exposed to either NaB, TSA or were left untreated. CAT levels were then determined after another 24 h. We found that promoter activity of the 0.38SRC1A-CAT and the 7145SRC1a-CAT vectors was inhibited by 80 -95% following treatment with TSA or NaB. For 0.38SRC1A-CAT, this level of inhibition was very similar to the reduction in CAT levels caused by mutations in both the GC1 and GA2 Sp1 binding sites (Figure 4) . We have previously demonstrated that individual mutations in GC1 or GA2 reduced basal activity of the SRC1A promoter by approximately 50% (Figure 4) . However, neither of these mutations was able to abrogate the effect of NaB or TSA on promoter activity. Taken together these results suggest that the observed repression of c-Src mRNA by NaB and TSA results primarily from transcriptional inhibition of both SRC promoters.
NaB and TSA do not alter protein binding patterns to either the SRC1A or SRC1a promoters Currently, it is believed that inhibition of HDAC activity by agents such as NaB and TSA favors overall histone acetylation mediated by the numerous HATs present in mammalian cells. This results in a more 'relaxed' chromatin conformation allowing access to transcription factors and the induction of a small number of specific genes. However, the mechanism by which such a process could lead to the inhibition of transcription is not immediately obvious.
Our previous characterization of the SRC1A promoter revealed that both Sp1 and the related family member Sp3 bind two critical sites we termed GC1 and GA2. However, only Sp1 was capable of transactivating SRC transcription and overexpression of Sp3 led to a down-regulation of promoter activity . Similarly, the activity of the SRC1a promoter was absolutely dependent on a HNF-1 site located at 735 to 756. Furthermore, the SRC1a promoter was Figure 2 Repression of c-Src levels by HDAC inhibitors is not affected by an inhibitor of protein synthesis. Total RNA was extracted from HepG2 cells following various periods of exposure to cyclohexamide (50 mM), or a combination of cyclohexamide (50 mM) and NaB (5 mM). RNA was examined by Northern analysis for c-Src and p21
WAF1 expression responsive to transactivation by only HNF-1a and not the related factor, HNF-1b . Thus, one possible mode by which HDAC inhibitors might negatively impact SRC expression is by favoring Sp3 and HNF-1b binding to the SRC1A and SRC1a promoters, respectively. Alternatively, signaling pathways activated by the change in HAT/HDAC activity might result in the inhibition of factors binding to the promoters or even induce the binding of previously unrecognized repressors. To begin to address these ideas we compared nuclear factor binding from control and TSA treated cells to both SRC promoters using EMSAs. In addition, we used probes encompassing substantial sections of both promoters, rather than typically short synthetic oligonucleotides, in order to more thoroughly characterize and compare the binding of factors to both promoters (see Figure 5a ). As shown in Figure 5b when a 164 bp fragment derived from the SRC1a minimal promoter was used as a probe in EMSA experiments we saw one major complex, previously identified as HNF-1a . There was no obvious change in this pattern when extracts from TSA treated cells were used. Similarly, when we used two DNA fragments from the SRC1A promoter encompassing the GC1 and GA2 Sp1 binding sites (Fragment A and Fragment B in Figure 5a ) we observed three species previously identified as specific Sp1 and Sp3 complexes . Again, as shown in Figure 5c and d, no major difference in the pattern of binding between extracts derived from control or TSA treated cells was discerned. Lastly, EMSAs using extracts derived from TSA treated cells produced no additional bandshifts that might implicate new protein species interacting with the SRC promoters. Taken together these results demonstrate that HDAC inhibitor mediated transcriptional repression of SRC does not appear to result from any obvious changes in the binding activities of Sp1 or HNF-1 family members to the SRC specific probes.
Discussion
HDAC inhibitors such as NaB and TSA are potent inducers of cell cycle arrest, differentiation and In addition, these agents have been shown to have antineoplastic activity in various animal model systems and are therefore being investigated as potential human chemotherapeutic drugs (Marks et al., 2001a,b) . Functionally, HDAC inhibitors are associated with highly selective changes in gene expression. This includes the induction of p21 WAF1 , which is essential for HDAC inhibitor mediated cell cycle arrest (Archer et al., 1998) . In this study we found that NaB or TSA treatment resulted in a significant down-regulation of c-Src gene expression in all tumor cell lines examined. The decrease in c-Src mRNA expression was transient during TSA treatment, which is likely a reflection of the shorter half-life of TSA compared with NaB in these cultured cells. Moreover, we found that inhibition of HDACs appeared to exert a direct effect on active SRC transcription, since cyclohexamide treatment was incapable of negating the action of NaB and TSA on cSrc expression. However, our most interesting and unusual observation was that NaB and TSA were capable of independently repressing both SRC promoters by 80 -95%. This is remarkable given the very different nature of the two SRC promoters and suggests down-regulation of c-Src expression must be of some functional significance. We also found that this transcriptional repression was not associated with any obvious change in the ability of Sp1 or HNF-1 family members to bind their respective SRC1A or SRC1a promoter sites. Nor did we detect any evidence in our EMSAs for new NaB or TSA dependent factors interacting with either SRC promoter. While considerable caution must be exercised extrapolating the results of in vitro bandshift assays to the actual situation at the SRC genomic locus, our data are currently consistent with the hypothesis that NaB and TSA exert their effect on the SRC1a and SRC1A promoters through the 758 to 735 HNF-1 and the GC1/GA2 Sp1 sites respectively. Indeed, for a SRC1A-CAT construct, the level of inhibition caused by TSA was very similar to the reduction in CAT levels caused by mutations in both the GC1 and GA2 Sp1 binding sites. In addition, individual mutations in either GC1 or GA2 were unable to block the effect of TSA on the SRC1A promoter, suggesting both of these Sp1 binding sites could play a role in mediating the effect of these agents. It is interesting to note that both Sp1 and HNF-1 are highly versatile transcriptional regulators capable of interacting with a wide variety of other transcription factors, co-activators, and repressors as well as components of the general transcriptional machinery (Chiang and Roeder, 1995; Doetzlhofer et al., 1999; Lee et al., 1993; Soutoglou et al., 2000) . We speculate that in certain circumstances Sp1 and HNF1a may act through common intermediates or coactivators and that these factors may be the ultimate target of HDAC inhibitors.
The mechanism by which HDAC inhibitors bring about changes in gene expression is poorly understood but is generally assumed to result from local changes in histone acetylation status. The observation that many common co-activators such as p300/CBP and pCAF have intrinsic HAT activity, while repressor complexes such as YY1 and mSin3 are associated with HDAC activity, has strengthened this model (Kouzarides, 2000) . Studies have also identified local regions of increased histone acetylation in genes such as p21 WAF1 following treatment with HDAC inhibitors (Richon et al., 2000) . Interestingly, several groups have demonstrated that this induction of p21 WAF1 occurs independently of p53 and have mapped the essential elements to one or more critical Sp1 binding sites located in the p21 WAF1 minimal promoter (Han et al., 2001; Huang et al., 2000; Nakano et al., 1997) . Indeed, many of the aspects we have described concerning the repression of the SRC gene were mirrored by the behavior of p21 WAF1 .
(1) The dose of NaB required for maximal repression of c-Src mRNA was very similar to that required for maximal induction of p21 Sowa et al., 1999) we could determine no obvious difference in relative binding of transcription factors to their respective cis elements before and after TSA treatment. It is therefore possible that the events leading to the critical induction of p21 WAF1 by HDAC inhibitors are shared by those which result in c-Src repression.
While local increases in histone acetylation present an attractive model for gene activation by HDAC inhibitors it is less obvious how this could lead to specific repression of genes. Indeed, relatively few genes are induced by these agents (Van Lint et al., 1996) ; most remain unaffected while some including c-myc and the subject of this study c-Src, are actually repressed (Cuisset et al., 1997; Toscani et al., 1988) . It is also important to note that HATs are also capable of acetylating non-histone targets including transcription factors such as p53 (Gu and Roeder, 1997) and E2F1 (Martinez-Balbas et al., 2000) as well as cytoplasmic proteins such as a-tubulin (Maruta et al., 1986) and importin a (Bannister et al., 2000) . It is therefore conceivable that the HDAC inhibitor mediated downregulation of the SRC promoters is controlled by events other than histone acetylation/ deacetylation. For example, recent work on the induction of histone H18 and repression of c-myc by NaB has pointed to the activation of specific okadaic acid sensitive serine/threonine phosphatases as being essential for the observed effects (Cuisset et al., 1997) . In addition, it was reported recently that inhibitors of serine/threonine kinases were also capable of negating the effects of NaB mediated induction of the human choline acetyltransferase gene (Espinos et al., 1999) . Lastly, induction of p21 WAF1 by HDAC inhibitors could be blocked by treatment with specific inhibitors of Protein Kinase C (Han et al., 2001) . Taken together these reports suggest that the change in gene expression profiles mediated by HDAC inhibitors requires phosphorylation events in addition to histone modification. It will be of great interest to determine if a similar situation exists for repression of the SRC promoters by HDAC inhibitors.
Numerous studies over the years have implicated activation of c-Src as a contributing factor in the development of several important human cancers, especially those of the colon and breast. For example, anti-sense mediated downregulation of c-Src expression in HT29 cells results in decreased proliferation, colony forming ability and tumorigenicity (Staley et al., 1997) . In cells engineered to overexpress EGFR family members (to model a common finding in breast cancer) it was found that anti-sense mediated downregulation of c-Src led to growth arrest and apoptosis (Karni et al., 1999) . Clearly HDAC inhibitors also impact similar cellular processes inducing differentiation, growth arrest and/or apoptosis. We therefore suggest that the widespread downregulation of c-Src we have described contributes significantly to these important cellular responses. We feel this observation may be particularly relevant to the human colon where cells are naturally exposed to high levels of NaB and where a role for cSrc in the development of neoplasia is well described. Confirmation of these hypotheses will require further experimental investigation but strengthens the argument that drugs designed to down regulate c-Src expression or activity may well be an additional weapon to target a number of different important human cancers.
Materials and methods

Cell culture
The cell lines used in this study were all obtained from the American Type Culture Collection (ATCC). The HT29 and SW480 human colon cancer cell lines were grown in DMEM media and 10% fetal calf serum (Gibco). T-47D breast ductal carcinoma cells were propagated in RPMI 1640 medium with 2 mM L-glutamine and 0.2 U/ml bovine insulin (Eli Lilly). The HepG2 hepatocellular carcinoma cell line was grown in DMEM F-12 media with 10% fetal calf serum. All cells were maintained at 378C and 5% CO 2 . For drug studies, exponentially growing cells were trypsinized, seeded at 50% confluency, grown for 24 h, and then treated with 5 mM NaB (Sigma Aldrich), 1 mM trichostatin-A (Sigma), 50 mM cyclohexamide (Sigma), or combinations of these drugs. Cells were then harvested in specific lysis buffers at various time points following treatment. For dose response studies, cells were exposed to the appropriate concentration of drug for 24 h, and then harvested.
Plasmid constructs
Plasmid based c-Src cDNA clones have been described previously (Dehm et al., 2001 ). An expression plasmid containing the p21 WAF1 coding region was purchased from the ATCC. The SRC1A and SRC1a promoter constructs p0.38SRC-CAT, p0.38SRCGC1mut-CAT p0.38SRCGA2-mut-CAT and 7145SRC1a-CAT have been described previously Ritchie et al., 2000) .
RNA extraction and Northern blot analysis
Following drug treatment, total cellular RNA was isolated according to the method of Chomczynski and Sacchi (1987) and equal amounts (15 mg per lane) were fractionated on 1% denaturing formaldehyde-agarose gels. RNA was transferred to Gene Screen nylon membranes (DuPont), UV cross-linked, and then hybridized with cDNA probes specific for c-Src or p21 labeled with a 32 P-dCTP using an Oligolabeling kit (Pharmacia). Phosphorimage analysis was performed with a BioRad Molecular Imager FX following exposure to a KScreen (Kodak); alternatively autoradiography was performed at 7808C using an intensifier screen (Kodak).
Immunoblot analysis
Cells were harvested at various time points following drug treatment directly in a loading buffer containing 65 mM TrisHCl (pH 7.0), 2% (w/v) SDS, 5% b-mercaptoethanol, 10% (v/v) glycerol and 0.5% (w/v) bromophenol blue. Protein concentrations were subsequently determined using a kit based on a modified Lowry assay (Sigma). Equal amounts (typically 30 mg per lane) of protein were resolved on a 10% SDS-polyacrylamide gel, followed by transfer to nitrocellulose and membrane blocking using standard procedures . Blots were incubated with an antibody specific for c-Src (Oncogene Research Products) at a final concentration of 100 ng/ml, washed, and probed with an anti-mouse secondary antibody conjugated to horseradish peroxidase (Santa Cruz) diluted 1 : 2000 as described . Membranes were immersed in chemiluminescence reagents (Pierce) and exposed to Kodak X-Omat Blue XB-1 film for signal detection.
Transient transfections and CAT assays
All plasmid constructs used in transfection experiments were isolated and purified using an EndoFree Plasmid Maxi Kit from Qiagen. In a typical transfection experiment, 1.5 mg of a promoter CAT construct, 0.5 mg of pCMVb-Gal, and 10 ml of Superfect reagent (Qiagen) were mixed together in 85 ml of OptiMEM (Invitrogen Life Technologies). After a 20 min incubation at room temperature, the DNA-Superfect mixture was further diluted with 600 ml of DMEM (for SW480) or DMEM F-12 (for HepG2) cell culture media with 10% FCS. This transfection mix was then added directly to plates seeded the previous day at a density of 4610 5 cells per 35 mm tissue culture plate. Transfections were allowed to proceed for 3 h followed by regular growth after the addition of 2 ml of cell culture media (DMEM for SW480, DMEM F-12 for HepG2). After 24 h, the cells were either exposed to NaB (5 mM), TSA (1 mM), or left untreated. Cells were harvested after an additional 24 h and processed in a lysis buffer provided with a CAT ELISA kit (Roche Diagnostics). Protein concentrations of cell lysates were determined using Bradford reagent (Bio-Rad). b-Galactosidase activity was assayed as described . CAT levels were analysed using a CAT ELISA kit, corrected for both protein concentration and b-Galactosidase activity where appropriate. Data presented was the result of two such experiments, each performed in duplicate.
Electrophoretic mobility shift assay (EMSA)
HepG2 cells were harvested at various time points following treatment with 1 mM TSA, and nuclear extracts were prepared by the method of Andrews (Andrews and Faller, 1991) . Protein concentrations were quantified using a Lowry Kit (Sigma). A 32 P-dCTP labeled probe encompassing the 7145 to +19 region of the SRC1a promoter was prepared using Klenow fragment in an in-fill reaction of a ClaI HincII promoter restriction fragment as described . The SRC1A EMSA probes A (120 bp) and B (60 bp) were prepared simultaneously by digestion of p0.38SRC-CAT with NarI and BssHII, followed by a Klenow in-fill reaction with [a 32 P]-dCTP, and subsequent agarose gel purification . EMSA reactions consisting of 5 mg of nuclear extract and 4610 5 c.p.m. of the appropriate probe were performed exactly as described .
